Third Rock Ventures

Tango Therapeutics is leveraging the principle of synthetic lethality to develop genetically targeted therapies for specific tumors, focusing on genetically defined subsets of cancers with limited treatment options.

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing breakthrough precision medicines for common diseases, particularly chronic kidney disease, leveraging insights from human genetics and their proprietary Maze Compass platform.

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of precision small molecule medicines for central nervous system (CNS) disorders. Their RAP technology platform allows for targeted drug development that aims to reduce side effects associated with traditional neuroscience drugs.

Septerna is a biotechnology company focused on pioneering GPCR drug discovery through its proprietary Native Complex Platform™, aiming to develop oral small molecule therapies targeting GPCRs across various therapeutic areas.

Sage Therapeutics is an award-winning biopharmaceutical company with over 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases.

Blueprint Medicines is focused on developing innovative therapies for patients with mast cell disorders and solid tumors, utilizing a proven drug discovery platform and robust clinical development infrastructure.

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health disorders. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms of action, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.

Azalea Therapeutics is enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo. The company uses precision genome editing tools to engineer T cells within the patient, employing Envelope Delivery Vehicles (EDVs) to deliver genetic modifications safely and effectively.

Insitro is a drug discovery company that leverages machine learning and large-scale data to develop new medicines more efficiently. They focus on understanding complex biological systems to create transformative therapies in areas such as metabolism, oncology, and neuroscience.

Flare Therapeutics is focused on developing small molecule medicines that target transcription factors to treat diseases, particularly in precision oncology. Their pipeline includes programs for advanced urothelial cancer and prostate cancer, leveraging a unique approach to drug discovery.

Candid Therapeutics is a biotech company focused on developing treatments for fungal infections.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Seed and early-stage investor that creates and invests in biotech startup companies, emphasizing company creation.

5AM Ventures focuses exclusively on the earliest stages of life sciences companies, often investing at or before seed stage and operating an in-house company-creation engine called the 4:59 Initiative. The firm combines hands-on involvement with partners taking short-term operating roles and remaining deeply engaged throughout a company's life, alongside systematic focus on capital efficiency and faster realizations.

Creates and seeds about half its portfolio companies from in-house discovery labs (Ridgeline in Basel, Highline in New York), seeding them with tens of millions and re-running key experiments, importing big-pharma discipline into venture-backed biotech.

Invests in early-stage life sciences companies, often backing founders when they are no more than an idea.